SCHEMBL15035280

SCHEMBL15035280

C=C1C=Cc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2N1C1C(=O)c2ccccc2NC1(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 6/20 0.52
JAK2 O60674 2/20 0.44
CDK4 P11802 7/20 0.44
CCND1 P24385 6/20 0.44
CCND3 P30281 6/20 0.44
CCND2 P30279 5/20 0.44
ALK Q9UM73 1/20 0.43
DCLK1 O15075 1/20 0.42
LRRK2 Q5S007 1/20 0.42
CDK9 P50750 2/20 0.42
CCNT1 O60563 1/20 0.42
AURKA O14965 1/20 0.41
PLK1 P53350 1/20 0.41
CCNA2 P20248 3/20 0.41
CDK2 P24941 3/20 0.41
CCNE2 O96020 2/20 0.41
CCNE1 P24864 2/20 0.41
CCNA1 P78396 2/20 0.41
PAK4 O96013 1/20 0.41
PAK1 Q13153 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15035263 0.85 TNK2 (0.48) TNK2CDK4CCND1CCND3CCND2
SCHEMBL15035487 0.82 MARK3 (0.38) TNK2JAK2BRD4
SCHEMBL15041561 0.79 CDK4 (0.64) TNK2JAK2CDK4CCND1CCND3
SCHEMBL15035271 0.78 CDK4 (0.50) TNK2JAK2CDK4CCND1CCND3
SCHEMBL15035264 0.76 CDK4 (0.51) TNK2JAK2CDK4CCND1CCND3
SCHEMBL15035273 0.74 FGFR1 (0.57) TNK2CDK4CCND1CCND3CCND2
SCHEMBL15035284 0.73 CDK4 (0.51) TNK2JAK2CDK4CCND1CCND3
SCHEMBL15035278 0.73 CDK4 (0.50) TNK2JAK2CDK4CCND1CCND3
SCHEMBL15035375 0.72 CDK4 (0.48) TNK2JAK2CDK4CCND1CCND3
SCHEMBL16510430 0.72 PAK1 (0.62) TNK2JAK2CDK4CCND1CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 TNK2 7/4885JAK2 720/4885CDK4 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.